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Background: The indeterminate fine needle aspiration biopsy (FNAB) results present a clinical dilemma for
physicians. The aim of this study was to evaluate the diagnostic accuracy of fluorine-18 fluorodeoxyglucose positron
emission tomography (18 F-FDG PET) in the detection of these indeterminate lesions.
Methods: Seven studies (involving a total of 267 patients) published before November 2012 were reviewed.
Systematic methods were used to identify, select, and evaluate the methodological quality of the studies as well as
to summarize the overall findings of sensitivity and specificity.
Results: A total number of 70 patients were confirmed to have malignant lesions, with a cancer prevalence of
26.2% (70/267; ranging from 19.6% to 40.0% in these studies). The pooled sensitivity and specificity of PET or
PET/CT for the detection of cancer was 89.0% (95% CI: 79.0% ~ 95.0%) and 55.0% (95% CI: 48.0% ~ 62.0%),
respectively. There was no evidence of threshold effects or publication bias. The area [±standard error (±SE)] under
the symmetrical sROC curve was 0.7207 ± 0.1041. Although SUVmax was higher in malignant lesions (P < 0.01), there
was still a great overlap. The best cut-off value of SUVmax for differentiation was 2.05; but with a high sensitivity of
89.8% and low specificity of 42.0%.
Conclusion: F-FDG PET or PET/CT showed a high sensitivity in detecting thyroid cancers in patients with
indeterminate FNAB results. Further examination was strongly recommended when an FDG-avid lesion was
detected.
Keywords: Fluorine-18 fluorodeoxyglucose, Positron emission tomography, Meta-analysis, Thyroid nodule, Fine
needle aspiration biopsy, IndeterminateBackground
Thyroid cancer is the most common endocrine malig-
nancy. It represents approximately 1% of all cancers,
corresponding to an incidence of up to 56, 460 new
cases per year in the United States, with increasing inci-
dence over the last decades [1]. Early identification and
diagnosis is important in appropriate treatment of thy-
roid cancer, as delays in the diagnosis are associated with
increased mortality [2]. The major diagnostic challenge* Correspondence: luyingli2008@126.com
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reproduction in any medium, provided the orin the work-up of the large number of patients with thy-
roid nodules is to select for surgery only those patients
with malignant nodules.
Current guidelines recommend performing fine needle
aspiration biopsy (FNAB) for nodules with a diameter lar-
ger than 5 mm to 20 mm, depending on patient clinical
history and presence of suspicious ultrasonographic find-
ings [3]. FNAB is safe, easily performed, without major
complications, and cost-effective. However, a number of
reports have shown that between 11% and 42% of FNABs
of thyroid lesions are reported as indeterminate [4-6].
These cytological indeterminate nodules present a clinical
dilemma to the evaluating clinician. Therefore, patientstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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undergo diagnostic hemithyroidectomy to exclude malig-
nancy [7]. Because only 20% to 30% of these nodules are
malignant [8], most patients are undergoing unnecessary
thyroid surgery with the potential risk of irreversible
complications.
Unfortunately, at present, there is no alternative algorithm
for a more conservative management of patients with thy-
roid nodules of indeterminate cytopathology. As a molecular
image modality, Fluorine-18 Fluorodeoxyglucose (18 F-FDG)
PET can detect a wide variety of tumor sites [9]. Several
studies have reported the role of PET in assessing cytological
indeterminate nodules [10-18]. Nevertheless, the reduced
number of patients in these studies and the existence of
conflicting or non-conclusion results make it impossible to
draw a definite conclusion. The purpose of this study was to
meta-analyze published data on the diagnostic performance
of 18 F-FDG PET or PET/CT in predicting the correct diag-
nosis of cytological indeterminate thyroid nodules.
Methods
Search strategy
This project was approved by the institutional review
board at Shanghai Ninth People’s Hospital Affiliated to
Shanghai Jiaotong University School of Medicine. Stud-
ies were identified in the following electronic databases:
PubMed/MEDLINE and Embase databases. The search
was updated until November 2012 and no beginning
date limit was used. We searched articles by using the
key words: “PET”; “PET/CT”; “thyroid nodule”; “thyroid
incidentaloma”; “FDG”; “FNA”; “FNAB”; “indeterminate”;
“unsuspicious” or “non-conclusion”. Only English-language
was considered because the investigators were not familiar
with other languages. To expand our search, bibliographies
of articles that finally remained after the selection process
were screened for potentially suitable references.
Study selection
Two investigators independently evaluated potential
studies for inclusion and subsequently resolved disagree-
ments by discussion. Reviewers of the studies were
blinded to journal, author, institutional affiliation, and
date of publication. The selection criteria were: (i) adult
patients with thyroid nodule with indeterminate FNAB;
(ii) definite histological or follow up outcome; (iii) using
18 F-FDG PET or PET/CT for further diagnosis; (iv) a
study population of at least ten patients and (v) the
reported primary data were sufficient to allow calcula-
tion of both sensitivity and specificity. When data were
presented in more than one article, the article with the
largest number of patients or the article with the most
details was chosen.
Exclusion criteria were: (i) studies that presented re-
sults from a combination of different imaging modalitiesthat could not be differentiated for the assessment of a
single test date; (ii) animal studies and (iii) abstracts, re-
views, editorials, letters and comments.
Study quality
Quality appraisal of retrieved full-text articles was all
graded independently by 2 investigators for quality and
applicability according to the Quality Assessment Tool
for Diagnostic Accuracy Studies (QUADAS). This widely
used tool consists of 14 items that cover patient
spectrum, reference standard, disease progression bias,
verification and review bias, clinical review bias, incorp-
oration bias, test execution, study withdrawals, and
intermediate results [19,20]. Disagreements were re-
solved by consensus after a re-evaluation of the
references.
Data analysis
Data were reported according to the guidelines for
meta-analysis evaluating diagnostic tests. For each study,
the sensitivity, specificity and their 95% confidence inter-
vals (CI) were calculated from the original data. Positive
likelihood ratio (LR+), negative likelihood ratio (LR-),
and diagnostic odds ratio (DOR) were also reported. To
avoid calculation problems by having zero values, 0.5
was added to each cell of the respective contingency
table, which is a common method [21].
Because sensitivity and specificity often are related in-
versely because of the threshold effect, study heterogen-
eity in these diagnostic test characteristics was observed
using a summary receiver operating characteristic
(sROC) curve for which the area under the curve (AUC)
was calculated.
All meta-analyses (pooling and sROC analysis) were
performed using Meta-DiSc (version 1.4; Unit of Clinical
Biostatistics, Ramon y Cajal Hospital, Madrid, Spain) [22].
The Mann–Whitney U test were used to compare
PET findings between benign and malignant lesions. We
utilized ROC curve analysis to find the best cut-off value
of SUVmax for differentiation. Data was analyzed by
SPSS 13.0 software. All analyses were two-sided. A P




From the computer search and after extensive crosschecking
of reference lists, 283 abstracts were retrieved. Reviewing ti-
tles and abstracts revealed 18 articles potentially eligible for
inclusion. Thus, these 18 articles were retrieved in full text
version. Screening of the references of these articles did not
bring up new articles. Eleven articles were excluded from
meta-analysis because: (i) researchers in the articles did not
use histopathologic analysis and/or follow-up as the
Table 1 The characteristics of these 7 studies
Study Year Country Design Modality No. of patients Male/Female Age (Mean ± SD)
Kresnik [10] 2003 Austria NR PET 37 8/29 55.1 ± 13.8
de Geus-Oei [11] 2006 Netherlands Prospective PET 44 3/41 48.5 ± 13.8
Sebastianes [12] 2007 Brazil NR PET 42 4/38 45.3 ± 16.3
Hales [13] 2008 America Prospective PET/CT 15 1/14 47.5 ± 14.9
Smith [14] 2008 America Prospective PET 23 7/16 50*
Traugott [15] 2010 America Prospective PET, PET/CT 51 10/41 49.6 ± 10.6
Deandreis [16] 2012 France Prospective PET/CT 55 13/42 50.7 ± 10.5
NR not reported, SD the standard deviation; * The SD of the study was not reported.
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did not report data that could be applied to construct or
calculate true-positive, false-positive, true-negative, and/or
false-negative results (n = 3); (iii) lesion by lesion analysis
only (n = 1) and (iv) no FDG negative results (n = 1).
Therefore, 7 studies with 267 patients were finally included
in the meta-analysis.
Study description
The characteristics of these 7 studies were demonstrated
in Table 1. The selected studies were performed in
Austria [10], Netherland [11], Brazil [12], America
[13-15] and France [16]. The age of the patients included
in the selected studies ranged from 18 to 84 years, with
an average age ranging from 45.3 to 55.1 years. The sex
distribution was described in all of the 7 studies, and the
men-to-women ratio was 0.21 (46/221).
Among 7 studies, 4 were evaluated by PET [10-12,14],
2 were evaluated by PET/CT [13,16] and the other 1
was evaluated by either PET or PET/CT [15]. Most ofTable 2 The inclusion, exclusion criteria and definition of FDG
Study Year Inclusion criteria
Kresnik [10] 2003 All patients with TN; hypoechogenic or no uptake on sc
follicular or Hürthle cell proliferation on FNAB; scheduled
de Geus-Oei
[11]
2006 Palpable TN; FNAB: a follicular neoplasm or a Hürthle ce
neoplasm, if they showed atypical papillary cells, or if th
repeatedly insufficient; scheduled for hemithyroidectom
Sebastianes
[12]
2007 FNAB: hypercellular follicular and oxyphilic nodules sugg
neoplasm and also includes lesions that are suspect but
papillary carcinoma; scheduled for hemithyroidectomy
Hales [13] 2008 All patients with TN; either follicular or Hürthle cell lesio
Smith [14] 2008 Patients with a preoperative diagnosis of follicular neop
whom surgical excision was planned
Traugott
[15]
2010 Adults with TN or dominant TN; palpable or >1 cm on U
scheduled for surgery; FNAB: follicular lesion, Hürthle ce
lesion, atypical cytology, abnormal cytology, or suspiciou
Deandreis
[16]
2012 Patient age > 18 years; TN with a diameter≥ 1cm; FNAB
follicular lesions
TN: thyroid nodule, DM: diabetes mellitus.these studies were prospective [11,13-16], and the type
of two studies was not specified [10,12].
In all but 1 study [13], all patients had thyroid-
stimulating hormone (TSH) levels within the normal
range. 18 F-FDG PET studies were obtained from all pa-
tients at least 2 weeks after FNAB [11,12] while the
other 5 studies did not mention this interval [10,13-16].
The inclusion, exclusion criteria and definition of
FDG-PET positivity of these 7 studies were shown in
Table 2.
Study quality
Among the 7 studies, none of them reported the interval
between PET and surgery (QUADAS Item 4). Besides,
none of the reviewed articles interpreted the 18 F-FDG
PET and histology data in combination with other clin-
ical data that would be available in practice (QUADAS
Item 12). Only 2 articles described the methodology of
reference test in sufficient detail to permit replication
(QUADAS Item 9) [14,16], and only 1 article mentioned-PET positivity of these 7 studies
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Figure 1 The pooled sensitivity of PET or PET/CT for the detection of cancer.
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(QUADAS Item 11) [15].
Quantitative analysis (Meta-Analysis)
7 studies evaluated 267 patients with indeterminate
FNAB results. The pooled sensitivity of PET or PET/CT
for the detection of thyroid cancer was 89.0% (95% CI:
79.0% ~ 95.0%; I2 = 0.442; chi-square test with 6 degrees
of freedom [df] = 10.76; P = 0.0962). The pooled specifi-
city was 55.0% (95% CI: 48.0% ~ 62.0%; I2 = 0.309; chi-
square test with 6 df = 8.68; P = 0.1925). There
was no significant inconsistency among these studies
(Figures 1, 2). Therefore, a fixed-effects model was used to
calculate these pooled data. The overall LR+, LR- and
DOR were 1.87 (95% CI: 1.57 ~ 2.23), 0.24 (95% CI: 0.13 ~
0.45) and 8.15 (95% CI: 3.89 ~ 17.08), respectively. Besides,
the LR+, LR- and DOR for each of the studies were
presented in Table 3.
The sROC curve revealed no “shoulder-arm” plot,
suggesting no threshold effect. The area [±standard error
(±SE)] under the symmetrical sROC curve was 0.7207 ±
0.1041 (Figure 3).
Malignant lesions
A total number of 70 patients were confirmed to have
malignant lesions, with a cancer prevalence of 26.2%
(70/267; ranging from 19.6% [15] to 40.0% [13,16]).Figure 2 The pooled specificity of PET or PET/CT for the detection ofAmong them, 36 (51.4%) lesions were confirmed to be
papillary cancers, 16 (22.9%) lesions were follicular
cancers, the rest were other types of malignant tumors.
18 F-FDG PET or PET/CT correctly detected 62 lesions
(88.6%). There were 8 false negative cases: 5 papillary
cancers and 3 tumors of uncertain malignant potential
(TUMP).
Benign lesions
197 patients were confirmed to have benign lesions. 107
(54.3%) lesions were diagnosed as adenomas (follicular
adenoma: 83, Hürthle cell adenoma: 12 and oxyphilic
adenoma: 12), 55 (27.9%) as nodular hyperplasia, 29
(14.7%) as multinodular goiters and the other 6 (3.1%) as
thyroiditis. PET or PET/CT only correctly judged 108 le-
sions (54.8%). There were considerable false positive
cases: 48 adenomas (follicular adenoma: 28, Hürthle cell
adenoma: 12 and oxyphilic adenoma: 8), 19 nodular
hyperplasia, 18 multinodular goiters and 4 thyroiditis.
The differentiation of malignant and benign lesions
6 studies described age and gender in detail [10-13,15,16].
We found there was no statistical difference of age or sex
between malignant and benign lesions (P > 0.05). 5 studies
analyzed diameters, and the diameter could not be used to
differentiate malignant and benign lesions, either (P > 0.05)
[10,12,13,15,16]. 4 studies listed SUV in detail [10,12,13,16].cancer.
Table 3 Reported LR+, LR-, and DOR of these 7 studies
Study Year TP TN FP FN LR + (95% CI) LR- (95% CI) DOR (95% CI)
Kresnik [10] 2003 10 15 12 0 2.14 (1.39 ~ 3.29) 0.08 (0.01 ~ 1.26) 26.04 (1.39 ~ 489.26)
de Geus-Oei [11] 2006 6 25 13 0 2.68 (1.66 ~ 4.33) 0.11 (0.01 ~ 1.59) 24.56 (1.28 ~ 469.69)
Sebastianes [12] 2007 11 12 19 0 1.57 (1.16 ~ 2.13) 0.11 (0.01 ~ 1.66) 14.74 (0.80 ~ 273.13)
Hales [13] 2008 5 3 6 1 1.25 (0.70 ~ 2.24) 0.50 (0.07 ~ 3.75) 2.50 (0.19 ~ 32.19)
Smith [14] 2008 5 8 10 0 1.66 (1.04 ~ 2.66) 0.19 (0.01 ~ 1.16) 8.90 (0.43 ~ 184.86)
Traugott [15] 2010 8 25 16 2 2.05 (1.25 ~ 3.35) 0.33 (0.09 ~ 1.16) 6.25 (1.17 ~ 33.26)
Deandreis [16] 2012 17 20 13 5 1.96 (1.21 ~ 3.17) 0.38 (0.17 ~ 0.85) 5.23 (1.55 ~ 17.67)
Pooled results 62 108 89 8 1.87 (1.57 ~ 2.23) 0.24 (0.13 ~ 0.45) 8.15 (3.89 ~ 17.08)
TP true positive, TN true negative, FP false positive, FN false negative.
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7.0 vs 5.0 ± 4.3; P < 0.01), there was still a great overlap. The
best cut-off value of SUVmax for differentiation was 2.05,
yet with a high sensitivity of 89.8% and low specificity
of 42.0%.Discussion
FDG-avid thyroid nodules detected on PET scan are at a
high risk of malignancy but the utility of 18 F-FDG PET
in the presurgical characterization of indeterminate thy-
roid nodules at cytology is controversial, due to discord-
ant results in the literature [16]. The most recent
American Thyroid Association (ATA) guidelines recom-
mend exploring any FDG-avid nodule by FNAB (recom-
mendation A1: Strongly recommends) but do not
recommend the routine presurgical use of PET to detect
malignancy (recommendation E: Recommends against) [3].Figure 3 The area under the symmetrical summary receiver operatingIn our meta-analysis, 18 F-FDG PET or PET/CT cor-
rectly detected 62/70 malignant lesions, with a very high
pooled sensitivity of 89.0%. Furthermore, SUV showed
valuable in differentiating malignant lesions from benign
ones (P < 0.01). We considered that PET was a useful
tool to predict malignancy.
Vriens et al. has already meta-analyzed the utility of
18 F-FDG PET in detecting patient with indeterminate
FNAB results [23]. Our pooled sensitivity and specifi-
city were similar to theirs. Compared with their ana-
lysis, our study was more up-dated and included more
patients in order to enhance our statistical accuracy.
Besides, we deleted one study with no FDG negative
results [17]; because LR- could not be calculated under
this circumstance, and with a specificity of 0%, which
would lead to inconsistency between studies.
Previous systemical study concluded that a false nega-
tive PET result only occurred in nodules with a greatestcharacteristic curve.
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were 8 false negative cases, and 5 lesions with a dimen-
sion ≥ 2.0 cm. Therefore, we thought the size was not
the sufficient reason to explain false negative phenom-
ena. Further studies should be performed to better dem-
onstrate it. Moreover, we noted that the majority of false
negative results occurred in one study [16]; but in this
study, the investigators regarded TUMP as malignant le-
sions, we thought it may cause bias and consequently
make more FDG false negative cases. We suggested
whether these patients had true malignant lesion should
be further investigated.
Variable physiologic FDG uptake, and asymmetric
FDG distribution in the neck can confound image inter-
pretation. As a consequence, false positive is inevitable
[24]. We detected a considerable number of false posi-
tive cases in the analysis. The pooled specificity was only
55.0%. Therefore, we still should be very cautious when
making a conclusion of malignancy. Yang et al. once
demonstrated that the presence of focal uptake with
high SUVmax and calcification detected on CT images
correlates with a high likelihood of thyroid malignancy
[25]. Hence, we considered that sometimes we could
utilize CT imaging for reference in order to ameliorate
the diagnostic accuracy.
Currently, the cost of PET is relatively high; some
studies did not encourage it before thyroid surgery
[26,27]. However, there remained other reasons to con-
sider despite this cost-effectiveness. As in larger lesions,
the complication rates can be higher (because of exten-
sion toward the large vessels, trachea, or recurrent laryn-
geal nerve), and these patients may benefit most from
reassurance of a true-negative PET [23].
According to our analysis, PET correctly diagnosed
63.7% (170/267) of patients with indeterminate FNAB
results. Although there were some false positive cases,
over half patients (108/197) could avoid unnecessary
surgery after PET. We believed that PET was useful in
assisting treatment.
However, there are several limitations that are worth
mentioning, including publication bias, selector bias, or
diagnostic workup bias. For example, different studies
used different definition of FDG PET positivity and ma-
lignancy. Besides, some studies were evaluated by PET
while others were evaluated by PET/CT. Furthermore,
the heterogeneity of the population still existed, particu-
larly the vast variation in the prevalence of malignancy
in different parts of the world with both endemic goiter
areas and iodine-sufficient areas.
Conclusions
Our comprehensive meta-analysis of the literature revealed
that 18 F-FDG PET or PET/CT showed a high sensitivity in
detecting cancers in patients with indeterminate FNABresults. Further examination, such as hemithyroidectomy,
was strongly recommended when an FDG-avid lesion was
detected.
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